Adma Biologics opened higher at $13.23, compared with its previous close of $13.19. In the last trading session, the stock traded between $13.04 and $13.52. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Adma Biologics is now worth
$ 832.96
Giving a profit of
$ 732.96 (732.96%)
Invest with $1
Note: Past profits do not guarantee future returns.
ASCENIV revenue rose 31% YoY to $124.7 million, driving overall growth. Gross margin expanded 1,500 bps to 71%, boosting adjusted EBITDA by 32%. CEO Adam Grossman cites early-stage market penetration for ASCENIV. Pipeline candidate SG001 estimated to generate $300-500 million annually.
7 days ago
1Sep
Berger Montague probes ADMA Biologics board over alleged channel stuffing
Berger Montague investigates ADMA Biologics board for fiduciary duty breaches. Probe alleges channel-stuffing of flagship product ASCENIV despite declining demand. Shareholders can contact firm attorneys for details on the ongoing investigation.
2mo ago
21Aug
DJS Law Group joins ADMA Biologics securities fraud class action
DJS Law Group joins solicitation for lead plaintiff role in ADMA Biologics securities fraud class action. Investors who bought shares between August 9, 2024, and March 25, 2026, have until August 10, 2026, to apply. Lawsuit alleges channel stuffing and undisclosed related-party transactions inflated revenue growth. Stock dropped 29% in four days following a critical research report and analyst downgrade.
2mo ago
16Jul
Mizuho lowers ADMA Biologics price target to $17
Mizuho analyst Anthony Petrone maintained an Outperform rating on ADMA Biologics but lowered the price target from $20 to $17. The adjustment signals a revised valuation outlook while retaining a positive view on the stock's potential.
